IP & Partnerships

Elata Biosciences is uniquely positioned to capitalize on the burgeoning market for psychiatric intellectual property (IP). Our focus on preclinical drug development aligns seamlessly with the increasing interest from pharmaceutical companies seeking innovative solutions.

Recent industry trends underscore the growing demand for innovative therapeutics and the potential for substantial financial returns from strategic partnerships and licensing deals. For instance, Otsuka Pharmaceuticals acquired Mindset Pharma for approximately $60 million, despite Mindset having only a single preclinical drug asset in its pipeline. This acquisition exemplifies the significant value derived from preclinical drug assets and therapeutics that have achieved proof-of-principle. Other notable examples include Sosei Heptares' agreement with Neurocrine, where they received a $100 million upfront payment with potential milestone payments of up to $2.6 billion.

To maximize the value of our IP, we employ a rigorous, multi-faceted approach. Our scientists are incentivized to generate high-quality IP and explore potential commercialization strategies. This proactive approach ensures that valuable discoveries are protected and have the potential to translate into life-changing treatments.

Elata Biosciences aims to secure a significant share of the potential IP rights generated from community-funded research projects. By doing so, we can foster a collaborative environment where researchers and the broader community benefit from the fruits of their collective efforts.

Once a promising research project is identified, our development and legal teams conduct a thorough assessment of its IP potential. This rigorous evaluation process helps us identify patentable assets and develop robust IP strategies. By prioritizing IP protection, we aim to establish a strong foundation for future licensing and partnership opportunities.

Elata Biosciences is committed to building a diverse portfolio, which positions us as a valuable partner for pharmaceutical companies seeking to expand their pipeline and address unmet medical needs in psychiatry. By collaborating, we can leverage their expertise, resources, and global reach to advance our promising drug candidates through clinical trials and regulatory approval.

Elata Biosciences aims to:

• Accelerate Drug Development: Collaborate with industry leaders to advance promising drug candidates through clinical trials and regulatory approval.

• Drive IP Value: Secure upfront payments, milestone payments, and royalties from licensing and partnership agreements.

• Prioritize Token Sustainability: Deliver long-term value to ELATA through successful IP monetization

Elata Biosciences is dedicated to driving innovation in psychiatric medicine and delivering transformative treatments to patients. Our focus on IP and strategic partnerships will be instrumental in achieving this goal.